HHCP
OCUL icon

Hilton Head Capital Partners’s Ocular Therapeutix OCUL Stock Holding History

Hilton Head Capital Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.4K Buy
6,867
+2,347
+52% +$21.3K 0.03% 270
2026
Q1 		$38.3K Buy
4,520
+1,053
+30% +$10K 0.02% 350
2025
Q4 		$42.1K Buy
+3,467
New +$42.1K 0.02% 319

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hilton Head Capital Partners's OCUL Position: Q2 2026 in Review

Hilton Head Capital Partners increased its Ocular Therapeutix (OCUL) stake by 52% in Q2 2026, buying an estimated $21.3K and bringing the position to 6,867 shares worth $67.4K. The position accounts for 0.03% of the portfolio, ranked #270.

Hilton Head Capital Partners first reported a position in OCUL in Q4 2025 and has held it in 3 quarters since. 261 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Hilton Head Capital Partners held 6,867 shares of Ocular Therapeutix worth $67.4K as of Q2 2026.
  • Hilton Head Capital Partners bought 2,347 Ocular Therapeutix shares in Q2 2026, an estimated $21.3K.
  • Ocular Therapeutix made up 0.03% of Hilton Head Capital Partners's portfolio in Q2 2026, its #270 holding.
  • Hilton Head Capital Partners first reported a position in Ocular Therapeutix in Q4 2025 and has held it in 3 quarters since.
  • 261 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.